Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary Alma Welch

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
The Journal of Supportive Oncology|January 17, 2012
Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: the role of the midlevel practitionerMegan Cornelison, Elias J Jabbour, Mary Alma Welch
The Lancet. Haematology|August 31, 2023
Revisiting six established practices in the treatment of chronic myeloid leukaemiaHagop M Kantarjian, Mary Alma Welch, Elias Jabbour
Hematology (Amsterdam, Netherlands)|September 24, 2002
Skin infiltration with chronic lymphocytic leukemia is consistent with a good prognosisDawn E Colburn, Mary-Alma Welch, Francis J Giles
Clinical Lymphoma, Myeloma & Leukemia|November 1, 2011
Dasatinib combined with interferon-alfa induces a complete cytogenetic response and major molecular response in a patient with chronic myelogenous leukemia harboring the T315I BCR-ABL1 mutationA Megan Cornelison, Mary-Alma Welch, Charles Koller, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 20, 2023
Early Mortality as a Quality Indicator in Frontline and Salvage Acute Myeloid LeukemiaKoji Sasaki, Farhad Ravandi, Courtney DiNardo, et al.
Therapeutic Advances in Hematology|April 5, 2021
Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemiaJ Michael Savoy, Mary Alma Welch, Patrice E Nasnas, et al.
Leukemia Research|May 4, 2004
Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemiaPatricia Ault, Hagop Kantarjian, Mary Alma Welch, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 17, 2019
SOHO State of the Art Update and Next Questions: Advances in the Treatment of Adult Acute Lymphoblastic LeukemiaShilpa Paul, Caitlin R Rausch, Mary Alma Welch, et al.
Cancer|March 18, 2021
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approachHagop M Kantarjian, Tapan M Kadia, Courtney D DiNardo, et al.
Journal of Hematology & Oncology|March 17, 2023
The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decadesElias Jabbour, Nicholas J Short, Nitin Jain, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
The Journal of Supportive Oncology|January 17, 2012
Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: the role of the midlevel practitionerMegan Cornelison, Elias J Jabbour, Mary Alma Welch
The Lancet. Haematology|August 31, 2023
Revisiting six established practices in the treatment of chronic myeloid leukaemiaHagop M Kantarjian, Mary Alma Welch, Elias Jabbour
Hematology (Amsterdam, Netherlands)|September 24, 2002
Skin infiltration with chronic lymphocytic leukemia is consistent with a good prognosisDawn E Colburn, Mary-Alma Welch, Francis J Giles
Clinical Lymphoma, Myeloma & Leukemia|November 1, 2011
Dasatinib combined with interferon-alfa induces a complete cytogenetic response and major molecular response in a patient with chronic myelogenous leukemia harboring the T315I BCR-ABL1 mutationA Megan Cornelison, Mary-Alma Welch, Charles Koller, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 20, 2023
Early Mortality as a Quality Indicator in Frontline and Salvage Acute Myeloid LeukemiaKoji Sasaki, Farhad Ravandi, Courtney DiNardo, et al.
Therapeutic Advances in Hematology|April 5, 2021
Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemiaJ Michael Savoy, Mary Alma Welch, Patrice E Nasnas, et al.
Leukemia Research|May 4, 2004
Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemiaPatricia Ault, Hagop Kantarjian, Mary Alma Welch, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 17, 2019
SOHO State of the Art Update and Next Questions: Advances in the Treatment of Adult Acute Lymphoblastic LeukemiaShilpa Paul, Caitlin R Rausch, Mary Alma Welch, et al.
Cancer|March 18, 2021
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approachHagop M Kantarjian, Tapan M Kadia, Courtney D DiNardo, et al.
Journal of Hematology & Oncology|March 17, 2023
The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decadesElias Jabbour, Nicholas J Short, Nitin Jain, et al.
Pageof 2